MaxCyte Inc
NASDAQ:MXCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MaxCyte Inc
Total Receivables
MaxCyte Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MaxCyte Inc
NASDAQ:MXCT
|
Total Receivables
$3.5m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
9%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Total Receivables
$10.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
15%
|
|
|
Danaher Corp
NYSE:DHR
|
Total Receivables
$4.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Waters Corp
NYSE:WAT
|
Total Receivables
$828.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Total Receivables
$1.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Total Receivables
$3.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
MaxCyte Inc
Glance View
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
See Also
What is MaxCyte Inc's Total Receivables?
Total Receivables
3.5m
USD
Based on the financial report for Dec 31, 2025, MaxCyte Inc's Total Receivables amounts to 3.5m USD.
What is MaxCyte Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
9%
Over the last year, the Total Receivables growth was -25%. The average annual Total Receivables growth rates for MaxCyte Inc have been -36% over the past three years , -8% over the past five years , and 9% over the past ten years .
